Activated protein C resistance and anticoagulant proteins in young adults with central retinal vein occlusion

Acta Ophthalmologica Scandinavica

Volumn 77, Issue 6, 1999, Pages 634-637

  Larsson, J ^a   Hillarp, A ^b   Olafsdottir, E ^b   Bauer, B ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

Activated protein C resistance; Anticoagulant proteins; Factor V; Retinal vein occlusion

Indexed keywords

ANTICOAGULANT PROTEIN; ANTITHROMBIN III; CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT; PROTEIN C; PROTEIN S;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ANTITHROMBIN III DEFICIENCY; ARTICLE; ATHEROSCLEROSIS; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; DIABETES MELLITUS; FEMALE; GLAUCOMA; HUMAN; HYPERTENSION; MALE; ONSET AGE; PREVALENCE; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY;

EID: 0033429661     PISSN: 13953907     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0420.1999.770606.x     Document Type: Article

References (48)

1. Abu el Asrar AM, al Momen AK, al Amro S, Abdel Gader AG & Tabbara KF (1996): Prothrombotic states associated with retinal venous occlusion in young adults. Int Ophthalmol 20: 197-204.
2. Appiah AP & Greenidge KC (1987): Factors associated with retinal-vein occlusion in Hispanics. Ann Ophthalmol 19: 307-312.
3. Appiah AP & Trempe CL (1989): Risk factors associated with branch vs. central retinal vein occlusion. Ann Ophthalmol 21: 153-157.
4. Asherson RA, Khamashta MA, Ordi Ros J, Derksen RH, Machin SJ, Barquinero J, Outt HH, Harris EN, Vilardell Torres M & Hughes GR (1989a): The "primary" antiphospholipid syndrome: major clinical and serological features. Medicine Baltimore 68: 366-374.
5. Asherson RA, Merry P, Acheson JF, Harris EN & Hughes GR (1989b): Antiphospholipid antibodies: a risk factor for occlusive ocular vascular disease in systemic lupus erythematosus and the 'primary' antiphospholipid syndrome. Ann Rheum Dis 48: 358-361.
6. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA & Reitsma PH (1994): Mutation in blood coagulation factor V asociated with resistance to activated protein C. Nature 369: 64-67.
7. Bick RL (1997): Antiphospholipid thrombosis syndromes: etiology, pathophysiology, diagnosis and management. Int J Hematol 65: 193-213.
8. Castanon C, Amigo MC, Banales JL, Nava A & Reyes PA (1995): Ocular vaso-occlusive disease in primary antiphospholipid syndrome. Ophthalmology 102: 256-262.
9. Dahlbäck B, Hillarp A, Rosen S & Zoller B (1996): Resistance to activated protein C, the FV:Q506 allele, and venous thrombosis. Ann Hematol 72: 166-176.
10. Dahlbäck B (1994): Inherited resistance to activated protein C, a major cause of venous thrombosis, is due to a mutation in the factor V gene. Haemostasis 24: 139-151.
11. Dahlbäck B, Carlsson M & Svensson PJ (1993): Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 90: 1004-1008.
12. Denson KW, Reed SV & Haddon ME (1995): The modified APC resistance test [letter]. Thromb Haemost 74: 995.
13. Elman MJ, Bhatt AK, Quinlan PM & Enger C (1990): The risk for systemic vascular diseases and mortality in patients with central retinal vein occlusion. Ophthalmology 97: 1543-1548.
14. Favilla I, Stubbs K & Kowal L (1981): Abnormal fibrinolysis in retinal vein occlusion. Aust J Ophthalmol 9: 213-218.
15. Fong ACO, Schatz H, McDonald HR, Burton TC, Maberley AL, Joffe L, Zegarra H, Nadel AJ & Johnson RN (1991): Central retinal vein occlusion in young. Retina 11: 3-11.
16. Fong ACO & Schatz H (1993): Central retinal vein occlusion in young adults. Surv Ophthalmol 37: 393-417.
17. Ginsburg KS, Liang MH, Newcomer L, Goldhaber SZ, Schur PH, Hennekens CH & Stampfer MJ (1992): Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 117: 997-1002.
18. Glacet Bernard A, Bayani N, Chretien P, Cochard C, Lelong F & Coscas G (1994): Antiphospholipid antibodies in retinal vascular occlusions. A prospective study of 75 patients. Arch Ophthalmol 112: 790-795.
19. Gottlieb JL, Blice JP, Mestichelli B, Konkle BA & Benson WE (1998): Activated protein C resistance, factor V Leiden, and central retinal vein occlusion in young adults. Arch Ophthalmol 116: 577-579.
20. Greengard JS, Xiao Xiu XS, Fernandez JA, Griffin JH & Evatt B (1994): Activated protein C resistance caused by Arg506Gln mutation in factor Va. The Lancet 343: 1361-1362.
21. Hirota A, Mishima HK & Kiuchi Y (1997): Incidence of retinal vein occlusion at the Glaucoma Clinic of Hiroshima University. Ophthalmologica 211: 288-291.
22. Jorquera JI, Montoro JM, Fernandez MA, Aznar JA & Aznar J (1994): Modified test for activated protein C resistance [letter]. Lancet 344: 1162-1163.
23. Khamashta MA & Hughes GR (1995): Antiphospholipid antibodies and antiphospholipid syndrome. Curr Opin Rheumatol 7: 389-394.
24. Kleiner RC, Najarian LV, Schatten S, Jabs DA, Patz A & Kaplan HJ (1989): Vaso-occlusive retinopathy associated with antiphospholipid antibodies (lupus anticoagulant retinopathy). Ophthalmology 96: 896-904.
25. Larsson J, Olafsdottir E & Bauer B (1996): Activated protein C resistance in young adults with central retinal vein occlusion [see comments]. Br J Ophthalmol 80: 200-202.
26. Levine SR, Crofts JW, Lesser GR, Floberg J & Welch KM (1988): Visual symptoms associated with the presence of a lupus anticoagulant. Ophthalmology 95: 686-692.
27. Linna T, Ylikorkala A, Kontula K, Puska P & Tervo T (1997): Prevalence of factor V Leiden in young adults with retinal vein occlusion. Thromb Haemost 77: 212-216.
28. Majerus PW (1994): Human genetics. Bad blood by mutation. Nature 369: 14-15.
29. Malm J, Laurell M & Dahlback B (1988): Changes in the plasma levels of vitamin K-dependent proteins C and S and of C4b-binding protein during pregnancy and oral contraception. Br J Haematol 68: 437-443.
30. Malm J, Laurell M, Nilsson IM & Dahlbäck B (1992): Thromboembolic disease-Critical evaluation of laboratory investigation. Thrombosis and haemostasis 68: 7-13.
31. McGrath MA, Wechsler F, Hunyor ABL & Penny R (1978): Systemic factors contributory to retinal vein occlusion. Arch Intern Med 138: 216-220.
32. Pandolfi M, Isacson S & Astedt B (1972): Coagulation and fibrinolytic studies in 23 patients with occlusion of the retinal vessels. Acta Ophthalmol (Copenh) 50: 62-72.
33. Priluck IA, Robertson DM & Hollenhorst RW (1980): Long term follow-up of occlusion of the central retinal vein in young adults. Am J Ophthalmol 90: 190-202.
34. Pulido JS, Ward LM, Fishman GA, Goodwin JA, Froelich CJ & Sanghvi JP (1987): Antiphospholipid antibodies associated with retinal vascular disease. Retina 7: 215-218.
35. Rath EZ, Frank RN, Shin DH & Kim C (1992): Risk factors for retinal vein occlusions. A case-control study. Ophthalmology 99: 509-514.
36. Rees DC, Cox M & Clegg JB (1995): World distribution of factor V Leiden. Lancet 346: 1133-1134.
37. Ririe DG, Cosgriff TM & Martin B (1979): Central retinal vein occlusion in a patient with familial antithrombin III deficiency: case report. Ann Ophthalmol 11: 1841-1845.
38. Rosendaal FR, Koster T, Vandenbroucke JP & Reitsma PH (1995): High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 85: 1504-1508.
39. Snyers B, Lambert M & Hardy JP (1990): Retinal and choroidal vaso-occlusive disease in systemic lupus erythematosus associated with antiphospholipid antibodies. Retina 10: 255-260.
40. Svensson PJ, Zoller B & Dahlback B (1997): Evaluation of original and modified APC resistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls. Thromb Haemost 77: 332-335.
41. Svensson PJ & Dahlbäck B (1994): Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 330: 517-522.
42. Taberno MD, Tomas JF, Alberca I, Orfao A, Borrasca AL & Vicente V (1991): Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis. Am J Hematol 36: 249-254.
43. The Eye Disease Case-control Study Group (1996): Risk factors for central retinal vein occlusion. The Eye Disease Case-Control Study Group. Arch Ophthalmol 114: 545-554.
44. Trossaert M, Conard J, Horellou MH, Elalamy I & Samama MM (1996): The modified APC resistance test in the presence of factor V deficient plasma can be used in patients without oral anticoagulant [letter]. Thromb Haemost 75: 521-522.
45. Vine AK & Samama MM (1993): The role of abnormalities in the anticoagulant and fibrinolytic systems in retinal vascular occlusions. Surv Ophthalmol 37: 283-292.
46. Walters RF & Spalton DJ (1990): Central retinal vein occlusion in people aged 40 years or less: a review of 17 patients. Br J Opthalmol 74: 30-35.
47. Zöller B, Svensson PJ, He, X & Dahlbäck B (1994): Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 94: 2521-2524.
48. Zwierzina WD, Kunz F & Miller K (1985): Retinal vascular occlusion in antithrombin III deficiency. Klin Monatsbl Augenheilkd 187: 534-536.